Next Unicorns E11: insitro CEO Daphne Koller is optimizing drug discovery via machine learning | E1089

In this episode, Jason Calacanis chats with Daphne Koller, CEO & Co-Founder of insitro. They delve into the shift to remote education, the future of colleges, and why Daphne founded insitro. They discuss the role of machine learning in microbiology and drug discovery, funding for drug discovery companies, and insitro's disease focus. The conversation also touches on early drug trials, future health solutions, stem-cell research, and insitro's hiring needs.

Speakers

AI Chat

Unidentified

Jason Calacanis

Host • 37%

Daphne Koller

Guest • 60%

Unidentified

Chapters

0:00	Start
0:59	Jason intros Daphne Koller, CEO & Co-Founder of insitro
2:22	Daphne on the massive shift to remote education, what makes a great online course
10:02	Will college be changed forever?
15:35	Why Daphne started insitro
18:47	How machine learning plays into microbiology and drug discovery, why drug discovery is more expensive today than it has ever been
22:50	Who typically funds drug discovery companies? Why don't incumbent pharma companies utilize their data?
31:41	Which diseases are insitro going after first, and how are they approaching it with data?
38:30	Why we don't allow citizens to volunteer for early drug challenge trials for financial compensation & how COVID plays into that
49:20	How will current leading causes of death be solved over the coming decades?
55:30	Stem-cell research & breakthroughs, will human lifespans continue to increase?
1:00:10	GPT-3, are we in a simulation, is there a God?
1:05:40	What types of employees in insitro looking for?

Transcript

Clip

Loading transcript...